The 8-hour MOUD Training - PART 1 - 11/20/2023 (counts towards the DEA’s 8-hour training requirement)-Presentation Slides

Presentation Slides - Part 1 with Dr. Morrone

Pdf Summary

The document provides an overview of an 8-hour training course on the treatment of opioid use disorder (OUD) with Buprenorphine/Naloxone, conducted by the Provider Clinical Support System (PCSS). The course is partly funded by SAMHSA grants and doesn't necessarily reflect the views of the U.S. Department of Health and Human Services.<br /><br />**Speaker:**<br />Dr. William Morrone, an expert in addiction, pain management, and public health. He has extensive experience in naloxone distribution, drug courts, family medicine, and addiction education. He is also associated with the Michigan State University and Johns Hopkins School of Nursing.<br /><br />**Course Agenda:**<br />The training covers a range of topics within an 8-hour period, including:<br />1. Overview of addiction and OUD treatment (1 hour)<br />2. Patient evaluation (0.75 hours)<br />3. Specialty topics such as case studies and urine drug testing (1.75 hours)<br />4. Clinical uses of Buprenorphine (0.5 hours)<br />5. Overview of clinical tools (0.25 hours)<br /><br />**Definitions and Context:**<br />Addiction is defined as a chronic disorder involving compulsive drug seeking, brain circuitry changes, and potential for relapse. The prevalence of substance use disorders (SUDs) in medical settings highlights the need for effective treatment policies and practices.<br /><br />**Treatment Approaches:**<br />The course emphasizes a public health-oriented approach for treatment, which includes medications like Buprenorphine, Methadone, and Naltrexone/Naloxone. These medications aim to balance withdrawal management, reduction of cravings, and long-term recovery.<br /><br />**Challenges and Barriers:**<br />Problems include inadequate training for practitioners, insurance limitations, and stigma. Legislative changes like the discontinuation of the DATA-Waiver Program are also discussed, which affects prescribing practices for Buprenorphine.<br /><br />**Different Populations:**<br />Treatment considerations are provided for special populations such as pregnant women, those with co-occurring psychiatric disorders, adolescents, and individuals with compromised renal or hepatic function.<br /><br />**Clinical Application:**<br />Practical instructions on the initiation, stabilization, and maintenance of Buprenorphine treatment are included, along with case studies that highlight real-life challenges and strategies in managing OUD.<br /><br />**Tools and Resources:**<br />The course also stresses the importance of urine drug testing, patient evaluation, and using clinical tools effectively. References and further reading materials are provided to ensure comprehensive understanding and practical application.<br /><br />**Summary:**<br />The training concludes that medications for OUD are effective in reducing illicit opioid use and improving treatment retention. It emphasizes the importance of ongoing education, interdisciplinary collaboration, and the use of evidence-based practices in addressing the opioid crisis.

Keywords

Opioid Use Disorder

Buprenorphine/Naloxone

PCSS

SAMHSA

Dr. William Morrone

Addiction Treatment

Public Health

Clinical Tools

Urine Drug Testing

Evidence-Based Practices